CorMedix Q2 2026 Results Reinforce Profitability but 2H26 Reimbursement Cliff Looms

What happened

CorMedix reported Q2 2026 consolidated revenue of $101.9 million, net income of $26.0 million, and adjusted EBITDA of $58.7 million, reflecting strong operating leverage in the current quarter. Management maintained full-year 2026 revenue guidance while raising adjusted EBITDA guidance, signaling confidence in cost control and Melinta integration synergies. The adjusted EBITDA margin of approximately 58% is unusually high and may benefit from favorable mix or one-time items, so investors should not extrapolate directly. Revenue was not revised upward, which implies the company still expects a material sequential decline in the second half as the TDAPA reimbursement step-down takes effect on July 1, 2026. The results validate the front-weighted 2026 strategy but leave the core question of post-reset revenue durability unanswered.

Implication

The Q2 print reinforces the front-loaded 2026 plan: robust adjusted EBITDA of $58.7 million annualizes near $235 million, but management's moderate guidance raise implies a steep expected 2H26 decline after TDAPA resets. Maintained revenue guidance suggests DefenCath volume is tracking as planned, yet no new adoption KPIs were disclosed, leaving the utilization offset unverified. The raised EBITDA guidance is a positive signal for Melinta synergies and cost discipline, but investors should confirm that the increase reflects durable operating leverage rather than one-time items or delayed opex. With the stock currently at $7.03 and a known reimbursement cliff just two months away, the fundamental question is whether post-reset quarterly EBITDA run-rate can support valuations above current levels. Until Q4 2026 results demonstrate revenue and EBITDA stabilization under post-TDAPA economics, the risk/reward favors holding rather than aggressive accumulation.

Thesis delta

No change to thesis direction, but conviction increases modestly. The Q2 2026 adjusted EBITDA beat and raised guidance suggest that the 1H26 utilization and synergy plan is executing ahead of schedule, strengthening the bear-case floor. However, the maintained revenue guidance underscores that the 2H26 reimbursement step-down is still expected, and the thesis remains dependent on post-TDAPA unit stabilization rather than a single strong quarter.